Lindsey Rigsby
Primary Care · Dallas, TXNPI 1700456944
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Novo Nordisk at 27.0% of the total. Among primary care clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 245 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$764
- GSK$500
- Indivior Inc.$349
- AstraZeneca$248
- Dexcom, Inc.$153
- plus $693 from 13 others
What the payments were for
- Food & beverage$3,707100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 119 | $1,001 |
| AbbVie | 39 | $764 |
| GSK | 27 | $500 |
| Indivior Inc. | 9 | $349 |
| AstraZeneca | 10 | $248 |
| Dexcom, Inc. | 7 | $153 |
| Bayer | 7 | $147 |
| Braeburn Inc. | 5 | $116 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $81 |
| Lundbeck LLC | 3 | $60 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $54 |
| Lilly USA, LLC | 2 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
| Pfizer | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Amgen | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Exact Sciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,707 in reported general payments places this provider in the 90th percentile of 563 primary care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 160 | $157,885 |
| RybelsusSemaglutide | 25 | $47,023 |
| VraylarCariprazine Hcl | 23 | $42,173 |
| JardianceEmpagliflozin | 28 | $41,676 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $40,052 |
| FarxigaDapagliflozin Propanediol | 39 | $28,836 |
| EliquisApixaban | 20 | $22,370 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $16,579 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $16,277 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $14,806 |
| MyrbetriqMirabegron | 12 | $10,743 |
| LinzessLinaclotide | 14 | $9,962 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $7,519 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,598 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $6,409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,001 | $204,908185 claims |
| AbbVieVraylar, Linzess | $764 | $52,13537 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $500 | $46,65063 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $248 | $45,41560 claims |
| PfizerEliquis | $38 | $22,37020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 563 primary care providers in Texas.
Other primary care in Dallas
- Herbert BautistaDallas$14K
- Carmen SaloneDallas$4K
- Jennifer ClarkDallas$4K
- Mary GibbensHouston$42K
- Phillip GulleySan Antonio$23K
- Brandi JoynerLongview$12K
- Steven ParisAustin$10K
- Hope OdomCollege Station$10K
- Arlena GraysTomball$9K
- Charlotte BallardSan Antonio$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.